Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Phase 4

Completed

• Conditions: Glaucoma

• Registration Number: NCT00348023
• Lead Sponsor: Innovative Medical

Brief Summary

Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocular hypertension.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-06-30
• Study First Submitted QC: 2006-06-30
• Study First Posted: 2006-07-04
• Status Verified: 2007-02
• Last Update Submitted: 2007-02-07
• Last Update Posted: 2007-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• · Male or female > 18 years of age

  • Diagnosis of primary open-angle glaucoma or ocular hypertension
  • Untreated IOP > 18 mm Hg in each eye at the baseline evaluation
  • Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria

• · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication

  • Uncontrolled systemic disease
  • Active ocular disease other than POAG or ocular hypertension
  • Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
  • History of intraocular surgery within the last 3 months
  • Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Dr. Noecker; 🇺🇸 Pittsburgh, Pennsylvania, United States